{"id":"dimethazan","rwe":[{"pmid":"13559232","year":"1958","title":"Central nervous system stimulation and sedation with dimethazan.","finding":"","journal":"The American journal of the medical sciences","studyType":"Clinical Study"}],"tags":[{"label":"dimethazan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"elidin","offLabel":[],"synonyms":["dimethazan","elidin"],"timeline":[],"approvals":[],"brandName":"Elidin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"dimethazan","explanation":"Imagine your body's cells have locks on them, and Elidin is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. More research is needed to understand how Elidin interacts with cells and what effects it has on the body.","oneSentence":"Elidin is thought to work by interacting with a specific target in the body, although its exact mechanism of action is not well understood.","technicalDetail":"Elidin's mechanism of action is not well characterized, but it is believed to involve interaction with a specific molecular target, potentially affecting cellular signaling pathways or enzyme activity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3731","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIMETHAZAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:44:00.209700","biosimilars":[],"competitors":[],"genericName":"dimethazan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007418","UNII":"H943V308AD","CHEBI":"CHEBI:135024","INN_ID":"778","UMLSCUI":"C0772350","ChEMBL_ID":"CHEMBL1739955","PUBCHEM_CID":"10612"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1958 Aug","pmid":"13559232","title":"Central nervous system stimulation and sedation with dimethazan.","journal":"The American journal of the medical sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Elidin, also known as Dimethazan, is a small molecule drug in the dimethazan class. Its target and exact mechanism of action are unknown, but it is not FDA-approved for any indications. The commercial status of Elidin is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to understand its potential uses and safety considerations. As a result, Elidin is not a widely recognized or used medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}